Share Price | ProKidney Corp. Stock Analysis & Recommendation

Q: What does ProKidney Corp. do?

Overview:ProKidney Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025)Most recent Net Profit: -38 Million (Quarterly Results - Mar 2025)Market-cap: USD 251.11 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: 0.33Return on Equity: 16.09%Price to Book: -0.25Contact Details:Registrar Address: Not available.

Q: Is ProKidney Corp. technically bullish or bearish?

As of 12 September 2025, the technical trend for ProKidney Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a mildly bullish daily moving average and a bullish indication from the Bollinger Bands on both weekly and monthly time frames. The KST is bullish on both weekly and monthly charts, while the MACD shows a mixed signal with a mildly bearish weekly and mildly bullish monthly reading. The Dow Theory indicates a mildly bullish monthly trend, but the OBV is mildly bearish on the monthly. In terms of performance, ProKidney has returned 60.36% year-to-date, significantly outperforming the S&P 500's 12.22% over the same period, although it has underperformed the index over the past year with a return of 13.39% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

254.45 k

Shareholding (Sep 2025)

FII

4.13%

Held by 28 FIIs

DII

81.64%

Held by 18 DIIs

Promoter

0.00%

How big is ProKidney Corp.?

22-Jun-2025

As of Jun 18, ProKidney Corp. has a market capitalization of 251.11 million, with net sales of 0.31 million and a net profit of -165.95 million over the latest four quarters. Shareholder's funds are at -994.95 million, and total assets are 442.14 million as of Dec 24.

View full answer

What does ProKidney Corp. do?

22-Jun-2025

ProKidney Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $38 million as of March 2025, with a market cap of $251.11 million. Key metrics include a debt-to-equity ratio of 0.33 and a return on equity of 16.09%.

View full answer

Is ProKidney Corp. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, ProKidney Corp. shows a mildly bullish trend with a year-to-date return of 60.36%, outperforming the S&P 500's 12.22%, but underperforming over the past year with a return of 13.39% compared to the S&P 500's 17.14%.

View full answer

Compare ProKidney Corp. with Similar Stocks

Seres Therapeutics, Inc.Nuvation Bio, Inc.MeiraGTx Holdings Plc

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 287 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.27

Return on Equity

15.27%

Price to Book

-0.28

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2025)

Net Profit:

-36 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

77.15%

6 Months

-15.2%

1 Year

-42.72%

2 Years

-85.66%

3 Years

-82.47%

4 Years

0.0%

5 Years

0.0%

ProKidney Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-86.65%

EBIT Growth (5y)

-160.67%

EBIT to Interest (avg)

-82.48

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.33

Sales to Capital Employed (avg)

-0.00

Tax Ratio

0.06%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

27.80%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.29

EV to EBIT

0.23

EV to EBITDA

0.24

EV to Capital Employed

0.03

EV to Sales

-41.50

PEG Ratio

Dividend Yield

ROCE (Latest)

13.55%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 23 Schemes (14.23%)

Foreign Institutions

Held by 28 Foreign Institutions (4.13%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 12.90% vs 2.14% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-37.10",
          "val2": "-47.80",
          "chgp": "22.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-35.80",
          "val2": "-41.10",
          "chgp": "12.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-177,599.10%",
          "val2": "0.00%",
          "chgp": "-17,759.91%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -20.61% vs 8.58% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-174.00",
          "val2": "-148.40",
          "chgp": "-17.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-163.30",
          "val2": "-135.40",
          "chgp": "-20.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,346,736.80%",
          "val2": "0.00%",
          "chgp": "-2,34,673.68%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.20

0.00

Operating Profit (PBDIT) excl Other Income

-37.10

-47.80

22.38%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-35.80

-41.10

12.90%

Operating Profit Margin (Excl OI)

-177,599.10%

0.00%

-17,759.91%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 12.90% vs 2.14% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.10

0.00

Operating Profit (PBDIT) excl Other Income

-174.00

-148.40

-17.25%

Interest

0.00

Exceptional Items

-5.30

0.00

Consolidate Net Profit

-163.30

-135.40

-20.61%

Operating Profit Margin (Excl OI)

-2,346,736.80%

0.00%

-2,34,673.68%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -20.61% vs 8.58% in Dec 2023

All Annual Results

Company CV

About ProKidney Corp.

ProKidney Corp.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

ProKidney Corp.

1Day

52 Week

CASH

FII

DII

Promoter

How big is ProKidney Corp.?

Watch in Real-Time

What does ProKidney Corp. do?

Is ProKidney Corp. technically bullish or bearish?

Compare ProKidney Corp. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About ProKidney Corp.

Company Coordinates